Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31213025 | 0.83 | CYP1A2 (0.41) | CYP19A1ALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL31213026 | 0.80 | CYP1A2 (0.38) | CYP19A1ALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL26349402 | 0.78 | CYP19A1 (0.30) | CYP19A1 | |
| SCHEMBL22954505 | 0.76 | — | — | |
| SCHEMBL18074854 | 0.76 | TSHR (0.33) | CYP19A1ALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL28154094 | 0.75 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL8738806 | 0.74 | MME (0.31) | — | |
| SCHEMBL28155012 | 0.72 | CYP19A1 (0.30) | CYP19A1 | |
| SCHEMBL19068247 | 0.72 | — | — | |
| SCHEMBL27960370 | 0.71 | CES1 (0.35) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695240-B2 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695240-B2 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150051380-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | GENENTECH, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051380-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | GENENTECH, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-8900589-B2 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | GENETECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8900589-B2 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | GENETECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8389697-B2 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | GENENTECH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389697-B2 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | GENENTECH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120130059-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | BERIA ITALO (IT) | 2012-05-24 | — | — | US | disclosed |
| US-20120130059-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | BERIA ITALO (IT) | 2012-05-24 | — | — | US | disclosed |
| US-20100034837-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100034837-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051380-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | MRPL21, BCR, MYD88 | CYP19A1 2097/4885ALDH1A1 2716/4885SMN1; SMN2 3239/4885 |
| US-20100034837-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | MRPL21, BCR, MYD88 | CYP19A1 2097/4885ALDH1A1 2716/4885SMN1; SMN2 3239/4885 |
| US-20120130059-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | MRPL21, BCR, MYD88 | CYP19A1 2097/4885ALDH1A1 2716/4885SMN1; SMN2 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.